Q1 Earnings Estimate for CVKD Issued By Noble Financial

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Stock analysts at Noble Financial issued their Q1 2027 earnings per share (EPS) estimates for shares of Cadrenal Therapeutics in a note issued to investors on Monday, August 17th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($0.88) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.01) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.93) EPS and Q4 2027 earnings at ($0.92) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its earnings results on Thursday, August 13th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.28.

CVKD has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $13.00.

Cadrenal Therapeutics Price Performance

Shares of CVKD stock opened at $1.76 on Tuesday. Cadrenal Therapeutics has a one year low of $1.71 and a one year high of $14.64. The company’s fifty day moving average price is $2.66 and its 200-day moving average price is $4.76. The company has a market capitalization of $6.02 million, a price-to-earnings ratio of -0.36 and a beta of 1.84.

Institutional Investors Weigh In On Cadrenal Therapeutics

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in shares of Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the period. JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics in the third quarter worth $103,000. DRW Securities LLC purchased a new position in Cadrenal Therapeutics during the fourth quarter worth $171,000. Finally, Citadel Advisors LLC purchased a new position in Cadrenal Therapeutics during the third quarter worth $274,000. 7.92% of the stock is owned by institutional investors.

Insider Activity at Cadrenal Therapeutics

In other Cadrenal Therapeutics news, CEO Quang X. Pham sold 12,996 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $3.94, for a total transaction of $51,204.24. Following the sale, the chief executive officer directly owned 136,381 shares of the company’s stock, valued at $537,341.14. The trade was a 8.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 87,726 shares of company stock valued at $333,575. 14.59% of the stock is currently owned by company insiders.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.